CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project aims to develop a therapeutic vaccine that restores immune balance in the arterial wall to combat atherosclerosis, a major cause of cardiovascular disease. By inhibiting inflammatory responses, the vaccine seeks to significantly reduce the risk of cardiovascular events such as heart attacks and strokes.
Cardiovascular disease (CVD) is still a leading cause of death in the European Union (EU) accounting for nearly half of all deaths in Europe (48%).
In addition, CVD complications lead to a vast number of hospitalizations and thus to a great burden of health care costs in the EU.
Atherosclerosis and its final complication, plaque rupture and subsequent infarct in heart or brain, is the main underlying pathology of CVD and atherosclerosis is responsible for 70% of all cases of CVD.
Extensive studi…
UNIVERSITEIT LEIDEN
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Sweden, LUND
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Sweden, Stockholm
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
MEDIZINISCHE UNIVERSITAET WIEN
Austria, Wien
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
UGOT - GOETEBORGS UNIVERSITET/UNIVERSITY OF GOTHENBURG
Sweden, Goeteborg
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 sectors.
